Biosimilars for adalimumab (Humira) had similar efficacy and safety profiles for psoriasis when compared to the original. The meta-analysis appeared recently in the Journal of Dermatological Treatment ...

Biosimilars demonstrate comparable drug survival and safety with adalimumab among new users, but patients switching from Humira (the originator product) to biosimilars had a 35% higher discontinuation ...

The WHO added the biologics adalimumab and ustekinumab for psoriasis, sunscreen for people with albinism and urea- and ...

Share on Pinterest Humira will soon have a citrate-free biosimilar available on the market. Humira (adalimumab) is a popular medication used to treat various inflammatory conditions including ...

BOSTON, April 2 (Reuters) - Abbott Laboratories Inc. said on Monday it has filed an application with U.S. and European regulators to market its rheumatoid arthritis drug Humira as a treatment for the ...

Please provide your email address to receive an email when new articles are posted on . Simlandi (adalimumab-ryvk) hit the market as first interchangeable, citrate-free Humira biosimilar in a ...

ABT notes that Psoriasis patients experienced a significant reduction in the signs of their disease when treated with Abbott's HUMIRA, and they were significantly less likely to have their disease ...

The US Food and Drug Administration (FDA) has approved the biosimilar adalimumab-aaty (Yuflyma) in a citrate-free, high-concentration formulation, the manufacturer, Celltrion USA, announced today. It ...

Patients with HS on adalimumab have a 53% higher risk of serious infections than those with psoriasis. HS patients are more prone to sepsis and genitourinary infections, with longer hospital stays.

The FDA recently designated Yuflyma as "interchangeable" with the popular biologic Humira for the treatment of Crohn's disease and ulcerative colitis, two types of inflammatory bowel disease (IBD), ...